Efficacy and safety of Treamid in the rehabilitation of patients after COVID-19 pneumonia: a phase 2, randomized, double-blind, placebo-controlled trial

Table 4 Summary of the exploratory analysis in women

Predicted parameter	Characteristics of the model			Treamid superiority in women, p-value^b
Predicted parameter	Formular^a	R² (R²adj.), % F-statistic (df), p-value	Coefficient of Group:Sex interaction, p-value	Treamid superiority in women, p-value^b
Dyspnea Borg scale score	init:Group + init:Sex + Group:Sex	57.0 (53.6) F (4,50) = 16.6 p < 0.001***	−0.95 0.004**	0.6 0.001**
TLC, % pred.	init:Group + Group * Sex (median regression)	16.5 (pseudo-R²) F (5,52) = 5.59 p < 0.001***	11.37 0.028*	8.6 0.009**
Lung damage, %	init:Group + Group * Sex	22.9 (15.5) F (5,52) = 3.09 p = 0.016*	− 15.50 0.015*	6.4 0.127

Data in bold indicates significant p-value (< 0.05)
^a“:”—interaction term without main effect, “*”—interaction term with main effect
^bCalculated Treamid superiority in women adjusted for global mean of baseline values (2.01 for Borg scale, 97.9 for TLC, and 28% for lung damage)

ISSN: 1479-5876